The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever

Lorenzo Calligaris; Federico Marchetti; Alberto Tommasini; Alessandro Ventura

doi:10.1007/s00431-007-0547-3

The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever

Lorenzo Calligaris, Federico Marchetti, Alberto Tommasini, Alessandro Ventura

IRCCS pediatrico Burlo Garofolo

Research output: Contribution to journal › Article › peer-review

Abstract

Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention of both attacks and secondary amyloidosis. The overall nonresponder rate is about 5-10%. Anakinra is known to have good effectiveness in a severe autoinflammatory syndrome [chronic infantile neurological cutaneous and articular (CINCA) syndrome] and other recurrent hereditary periodic fevers. Pyrin-the protein involved in FMF-has a role in activating the proinflammatory cytokine interleukin (IL)-1β. We report the effectiveness of the addition of an IL-1-receptor inhibitor (anakinra) to colchicine in controlling the febrile attacks and acute phase response in an adolescent with FMF resistant to colchicine.

Original language	English
Pages (from-to)	695-696
Number of pages	2
Journal	European Journal of Pediatrics
Volume	167
Issue number	6
DOIs	https://doi.org/10.1007/s00431-007-0547-3
Publication status	Published - Jun 2008

Keywords

Anakinra
Colchicine resistance
Familial Mediterranean fever

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1007/s00431-007-0547-3

Cite this

@article{a8af44ba25844bebb1a29da2d4d17123,

title = "The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever",

abstract = "Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention of both attacks and secondary amyloidosis. The overall nonresponder rate is about 5-10%. Anakinra is known to have good effectiveness in a severe autoinflammatory syndrome [chronic infantile neurological cutaneous and articular (CINCA) syndrome] and other recurrent hereditary periodic fevers. Pyrin-the protein involved in FMF-has a role in activating the proinflammatory cytokine interleukin (IL)-1β. We report the effectiveness of the addition of an IL-1-receptor inhibitor (anakinra) to colchicine in controlling the febrile attacks and acute phase response in an adolescent with FMF resistant to colchicine.",

keywords = "Anakinra, Colchicine resistance, Familial Mediterranean fever",

author = "Lorenzo Calligaris and Federico Marchetti and Alberto Tommasini and Alessandro Ventura",

year = "2008",

month = jun,

doi = "10.1007/s00431-007-0547-3",

language = "English",

volume = "167",

pages = "695--696",

journal = "European Journal of Pediatrics",

issn = "0340-6199",

publisher = "Springer Berlin Heidelberg",

number = "6",

}

TY - JOUR

T1 - The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever

AU - Calligaris, Lorenzo

AU - Marchetti, Federico

AU - Tommasini, Alberto

AU - Ventura, Alessandro

PY - 2008/6

Y1 - 2008/6

N2 - Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention of both attacks and secondary amyloidosis. The overall nonresponder rate is about 5-10%. Anakinra is known to have good effectiveness in a severe autoinflammatory syndrome [chronic infantile neurological cutaneous and articular (CINCA) syndrome] and other recurrent hereditary periodic fevers. Pyrin-the protein involved in FMF-has a role in activating the proinflammatory cytokine interleukin (IL)-1β. We report the effectiveness of the addition of an IL-1-receptor inhibitor (anakinra) to colchicine in controlling the febrile attacks and acute phase response in an adolescent with FMF resistant to colchicine.

AB - Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention of both attacks and secondary amyloidosis. The overall nonresponder rate is about 5-10%. Anakinra is known to have good effectiveness in a severe autoinflammatory syndrome [chronic infantile neurological cutaneous and articular (CINCA) syndrome] and other recurrent hereditary periodic fevers. Pyrin-the protein involved in FMF-has a role in activating the proinflammatory cytokine interleukin (IL)-1β. We report the effectiveness of the addition of an IL-1-receptor inhibitor (anakinra) to colchicine in controlling the febrile attacks and acute phase response in an adolescent with FMF resistant to colchicine.

KW - Anakinra

KW - Colchicine resistance

KW - Familial Mediterranean fever

UR - http://www.scopus.com/inward/record.url?scp=41849105723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849105723&partnerID=8YFLogxK

U2 - 10.1007/s00431-007-0547-3

DO - 10.1007/s00431-007-0547-3

M3 - Article

C2 - 17588171

AN - SCOPUS:41849105723

VL - 167

SP - 695

EP - 696

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 6

ER -

The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this